Imipenem versus piperacillin/tazobactam for empiric treatment of neutropenic fever in adults

Internal Medicine Journal

Volumn 43, Issue 10, 2013, Pages 1151-1154

  Roohullah, A ^a   Moniwa, A ^a   Wood, C ^a,b   Humble, M ^a,c   Balm, M ^a   Carter, J ^a,c   Weinkove, R ^a,c  

^a CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

^b MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^c UNIVERSITY OF OTAGO WELLINGTON   (New Zealand)

Author keywords

Imipenem; Neutropenia; Piperacillin; Sepsis; Tazobactam

Indexed keywords

CILASTATIN PLUS IMIPENEM; FLUCONAZOLE; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ADULT DISEASE; AGED; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL; SYSTEMIC MYCOSIS;

IMIPENEM; NEUTROPENIA; PIPERACILLIN; SEPSIS; TAZOBACTAM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COHORT STUDIES; DRUG SUBSTITUTION; FEMALE; FEVER; HUMANS; IMIPENEM; MALE; MIDDLE AGED; NEUTROPENIA; PENICILLANIC ACID; PIPERACILLIN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885919234     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12226     Document Type: Article

References (17)

1. Bow EJ, Rotstein C, Noskin GA, Laverdiere M, Schwarer AP, Segal BH etal. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 2006; 43: 447-459.
2. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106: 2258-2266.
3. Savoie ML, Nevil TJ, Song KW, Forrest DL, Hogge DE, Nantel SH etal. Shifting to outpatient management of acute myeloid leukemia: a prospective experience. Ann Oncol 2006; 17: 763-768.
4. Weissinger F, Auner HW, Bertz H, Buchheidt D, Cornely OA, Egerer G etal. Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2012; 91: 1161-1174.
5. Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003; 44: 2069-2076.
6. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA etal. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: e56-93.
7. National Comprehensive Cancer Network. Prevention and Treatment of Cancer-Related Infections (Version 1.2013) 2013, [updated 2013 Feb 5; cited 2013 Jun 13]. Available from URL: http://www.nccn.org/professionals/physician_gls/pdf/infections.pdf
8. de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21 (Suppl 5): v252-256.
9. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H etal. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39: 31-37.
10. Paul M, Yahav D, Bivas A, Fraser A, Leibovici L. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev 2010; CD005197.
11. Tam CS, O'Reilly M, Andresen D, Lingaratnam S, Kelly A, Burbury K etal. Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee. Intern Med J 2011; 41: 90-101.
12. Chandrasekar PH, Arnow PM. Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer. Ann Pharmacother 2000; 34: 989-995.
13. Brack E, Bodmer N, Simon A, Leibundgut K, Kuhne T, Niggli FK etal. First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatr Blood Cancer 2012; 59: 423-430.
14. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R etal. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-3051.
15. Figuera R, Rivero N, Pajuelo F, Font P, Leyra F, De la Camara R etal. Initial empiric therapy of febrile neutropenia with antibiotic monotherapy. Piperacillin/tazobactam versus imipenem/cilastatin (1994-1996). Med Clin (Barc) 2001; 116: 610-611.
16. Oztoprak N, Piskin N, Aydemir H, Celebi G, Akduman D, Keskin AS etal. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital. Jpn J Clin Oncol 2010; 40: 761-767.
17. Vural S, Erdem E, Gulec SG, Yildirmak Y, Kebudi R. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia. Pediatr Int 2010; 52: 262-267.